Cases & Deals

Abbott invests in AuraSense Therapeutics

Clients Abbott Laboratories

Jones Day advised Abbott Laboratories, a leading global health care company, in connection with its purchase of Series B Convertible Preferred Stock in a private placement by AuraSense Therapeutics, LLC, a biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulation- and chemo-therapeutics for a variety of diseases.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.